Propranolol is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.
Propranolol is a non-selective beta-adrenergic receptor antagonist (beta-blocker) that has been investigated for use in neurodegenerative diseases, particularly for managing tremor in movement disorders and potential neuroprotective effects.
Propranolol works by blocking beta-1 and beta-2 adrenergic receptors, which has several relevant effects in neurodegenerative contexts:
Propranolol is first-line treatment for essential tremor, which overlaps with cerebellar degenerative conditions. The typical dose ranges from 40-320 mg/day divided doses[^1].
Used as adjunct for resting tremor in Parkinson's disease, particularly when levodopa-induced dyskinesias are present[^2].
Some studies suggest beta-blockers may help with gait and postural instability in certain PD subtypes.